diaDexus, Inc. announced that Kenneth C. Fang, M.D. will join the company as chief medical officer. Dr. Fang brings more than 25 years of experience as a physician-scientist with substantial corporate experience in biomarker discovery and applications for diagnostic product development and commercialization in diverse indications, including cardiovascular disease and inflammation. Prior to diaDexus, Dr. Fang was chief medical officer and vice president of translational research and clinical development at Integrated Diagnostics, where he led a comprehensive range of clinical activities, including clinical development, clinical operations, biometrics, medical affairs, project management and quality and regulatory affairs that contributed to the launch of Xpresys(TM) Lung.

The company also announced that Michael Richey, chief business officer, will be leaving the company effective September 30, 2014. The company has initiated a search for a chief commercial officer (CCO). Paul Manners will oversee the company's commercial operations in an interim role until the CCO role is filled.

Mr. Manners was previously vice president, Global Finance and Marketing at Novartis Diagnostics and also held executive finance and commercial positions within Johnson & Johnson's pharmaceutical and medical device businesses.